ESP-01 is under clinical development by Esperas Pharma and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to GlobalData, Phase II drugs for Gastrointestinal Stromal Tumor (GIST) have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ESP-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ESP-01 overview

ESP-01 is under development for the treatment of solid tumours including metastatic colorectal cancer, epithelial ovarian cancer, endometrial cancer, ewing sarcoma, soft tissue sarcoma, gastrointestinal stromal tumors (GIST), pancreatic cancer and triple-negative breast cancer (TNBC). It is administered by the oral route. The drug candidate acts by targeting checkpoint Kinase 1 (CHK 1).

Esperas Pharma overview

Esperas Pharma is a special purpose company created to develop one compound to proof-of-concept. The company is headquartered in Montréal, Quebec, Canada.

For a complete picture of ESP-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.